Testing new combinations of antibiotics to fight resistant infections
Official title: In vitro Pharmacokinetic/pharmacodynamic models for dose de-escalation of antibiotics
Funded at Ohio State University · NIH-11091620 · Data updated 2026-11-12
This study is looking at whether using two antibiotics together can help treat tough infections caused by MRSA, especially in people with medical devices, to find better ways to fight these stubborn infections.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | May 17, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $78,750 |
| NIH project number | 5R03AI183164-02 |
| Project ID | NIH-11091620 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with infections caused by MRSA, especially those with medical devices like artificial joints or bones.
✕Less likely to help
Patients with infections caused by bacteria other than MRSA or those not requiring antibiotic treatment may not benefit from this research.
What this research studies
This research investigates how combining two antibiotics, dalbavancin and daptomycin, can effectively treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA), particularly in patients with medical devices. The study uses advanced laboratory models that mimic the conditions of biofilm infections, which are notoriously difficult to treat due to their resistance to antibiotics. By examining the effectiveness of these combinations, the research aims to find better treatment options for patients suffering from these challenging infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with MRSA infections, reducing treatment failures and improving recovery rates.
How similar studies have gone: Previous research has shown that combining antibiotics can be effective against resistant bacteria, suggesting that this approach may yield promising results.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Kebriaei, Razi — Ohio State University
- Study coordinator: Kebriaei, Razi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.